Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-arm Phase II Study in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) to Evaluate Efficacy and Safety of Treatment With Single Agent Copanlisib and the Impact of Biomarkers Thereupon.

NCT02391116 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT02391116
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02391116 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-arm Phase II Study in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) to Evaluate Efficacy and Safety of Treatment With Single Agent Copanlisib and the Impact of Biomarkers Thereupon.
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
May 8, 2015
Completion date
January 19, 2018
Enrollment
67 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse, large b-cell, lymphoma